when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

PD-L1 · news · pharmadog

← back to PD-L1

News · PD-L1

29 stories

3dAstraZeneca scraps Phase 3 trial of new bispecific in lung cancerbiopharma dive

3dSTAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and morestat

3dAstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowbiospace

3dAstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowbiospace

3dAstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytrudafiercebiotech

22dMerck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combinationfiercebiotech

24dAstraZeneca has no plans to ramp up dealmaking in wake of Wainua failurebiospace

24dSummit, Merck must navigate new regulatory terrain in China-first cancer landscapebiospace

Jul 15, 26Merck ADC, in China study, shows potential to replace chemo in lung cancerbiopharma dive

Jul 15, 26Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytrudabiospace

Jun 9, 26Gilead and Merck’s latest trial success and flopstat

Jun 5, 26Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?biopharma dive

May 29, 26At ASCO, Merck makes case for a ‘cornerstone’ cancer drugbiopharma dive

May 16, 26Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With Neoadjuvant Gem-iDRS ± Cetrelimab in MIBConclive

May 14, 26HERIZON-GEA-01 Efficacy Results and Interpretation of Duration of Responseonclive

May 13, 26Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumorsonclive

May 12, 26GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026onclive

May 11, 26INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCConclive

May 8, 26Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026onclive

May 8, 26Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCLonclive

May 7, 26Dr Sznol on Optimal Treatment Sequencing in Melanomaonclive

May 7, 26Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROConclive

May 7, 26ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studiesonclive

May 7, 26Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026onclive

May 7, 26HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerationsonclive

May 7, 26Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEAonclive

May 6, 26Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinomaonclive

May 6, 26Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLConclive

May 6, 26Dr Sznol on Biomarkers of Response in Metastatic Melanomaonclive